A Study in Patients With Myasthenia Gravis in China

Launched by ASTRAZENECA · Nov 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how myasthenia gravis (MG) affects patients in China. It aims to understand the current treatment methods, how patients feel about their condition, and how the disease progresses. The study will involve around 1,200 patients diagnosed with MG from about 40 different locations across the country. Participants will be followed every six months until the end of 2027, allowing researchers to gather important information about the disease and its impact on daily life.

To join this study, patients of any age who have been diagnosed with MG are eligible, as long as they can provide their MG classification and a score that measures how the disease affects their daily activities. However, patients who have had a mild form of MG for over two years or those currently involved in another clinical trial cannot participate. This research is important for improving the understanding and treatment of MG, and it offers a chance for patients to contribute to valuable findings that could benefit others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians.
• 1. Patients must have the following data to be enrolled in this study:
• • MGFA classification
• • MG-ADL score
• • 2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF).
• Exclusion Criteria:
• • 1. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years;
• • 2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.